Latest 10-K annual reports

Sonim Technologies files an amendment to its annual report on Form 10-K to include information typically found in the proxy statement, which will be filed later than expected, and to provide updated certifications from its principal executive and financial officers.

Lifeway Foods files an amendment to its 2024 Annual Report on Form 10-K to include information required by Part III, covering directors, executive officers, compensation, and related matters.

Amedisys files Amendment No. 2 to its Form 10-K to include information required by Part III and updated certifications from the CEO and CFO.

First Financial Northwest files an amendment to its 2024 annual report to include Part III information due to the upcoming dissolution of the company after the acquisition of its banking operations by Global Federal Credit Union.

Genelux Corporation files an amendment to its annual report on Form 10-K to include Part III information regarding directors, executive officers, and corporate governance.

Logan Ridge Finance Corporation files an amendment to its annual report on Form 10-K to include previously omitted information regarding directors, executive officers, corporate governance, executive compensation, security ownership, related transactions, director independence, and principal accountant fees.

Volcon, Inc. files an amendment to its 2024 annual report, updating information on directors, executive officers, corporate governance, and executive compensation.

Kineta, Inc. files an amendment to its 2024 Annual Report on Form 10-K to include previously omitted information regarding directors, executive officers, corporate governance, and executive compensation.

Bluejay Diagnostics files an amendment to its annual report on Form 10-K to include previously omitted information regarding directors, executive officers, corporate governance, and recent board composition changes.

XBiotech Inc. amends its annual report on Form 10-K to include previously omitted information regarding directors, executive officers, and corporate governance.

BioNexus Gene Lab Corp. files an amendment to its 2024 annual report to include its policy on recovery of erroneously awarded compensation (clawback policy) to comply with SEC and Nasdaq regulations.

Kaya Holdings, a holding company in the wellness sector, reports a net loss for 2024 and suspends payroll due to capital constraints, despite progress in its psychedelic treatment center operations.

Sunrise Real Estate Group's 2024 annual report reveals a 37.2% decrease in net revenue and an increased operating loss compared to the previous year, primarily due to lower house sales.

Shopify files an amendment to its 2024 annual report to include Part III information regarding directors, executive officers, and corporate governance, along with updated certifications from the CEO and CFO.

Y-mAbs Therapeutics files an amendment to its 2024 Annual Report on Form 10-K to include Part III information and update the exhibit list, while also revising its non-employee director compensation policy.

Minerva Neurosciences files an amendment to its annual report to include missing Inline eXtensible Business Reporting Language (XBRL) data tagging.

FitLife Brands, Inc. files an amendment to its 2024 Annual Report on Form 10-K to restate information required by Items 10 through 15.

Starguide Group, Inc.'s 10-K filing reveals ongoing losses and a going concern uncertainty, but highlights the company's strategic shift towards becoming a SaaS incubator, with the acquisition of Live Investments Holdings and its LiveLead software.

Kairos Pharma, Ltd. files an amendment to its 2024 Annual Report on Form 10-K to include previously omitted exhibits related to securities description and executive compensation recovery policy.

Sentinel Holdings Ltd.'s 2024 10-K filing reveals a substantial revenue decline and a significant net loss, raising concerns about the company's financial stability and future operations.

Precigen files an amendment to its 2024 annual report to include information previously omitted from Part III, covering directors, executive officers, compensation, and corporate governance.

Nutriband Inc.'s 10-K filing reveals a widened net loss for fiscal year 2025, driven by increased research and development expenses for its AVERSA Fentanyl product and an impairment charge, despite a slight revenue increase.

Medalist Diversified REIT, Inc. files Amendment No. 1 to its Annual Report on Form 10-K/A, solely to amend and replace Part III of the Original Form 10-K.

DBV Technologies provides an overview of its ordinary shares, American Depositary Shares, corporate governance practices, and executive compensation in its amended 10-K filing.

Coya Therapeutics files an amendment to its annual report on Form 10-K/A to include previously omitted Part III information and updated certifications.

Evolv Technologies Holdings restates past financial statements following an investigation into sales practices and revenue recognition.

Ultralife Corporation files an amendment to its annual report on Form 10-K to include information on directors, executive officers, corporate governance, and executive compensation.

2seventy bio files an amendment to its 2024 Annual Report on Form 10-K to include previously omitted information regarding directors, executive officers, and corporate governance.

Rocket Companies files an amendment to its 2024 10-K report, detailing a planned Up-C structure collapse, acquisitions of Redfin and Mr. Cooper, and executive compensation.

XWELL, Inc. amends its original Form 10-K filing to include Part III information and updated certifications due to the absence of a definitive proxy statement.